Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry by Martin Höglund,

En presentation över ämnet: "Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry by Martin Höglund,"— Presentationens avskrift:

1 Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry by Martin Höglund, Fredrik Sandin, Karin Hellström, Mats Björeman, Magnus Björkholm, Mats Brune, Arta Dreimane, Marja Ekblom, Sören Lehmann, Per Ljungman, Claes Malm, Berit Markevärn, Kristina Myhr-Eriksson, Lotta Ohm, Ulla Olsson-Strömberg, Anders Själander, Hans Wadenvik, Bengt Simonsson, Leif Stenke, and Johan Richter Blood Volume 122(7): August 15, 2013 ©2013 by American Society of Hematology

2 Age- and sex-specific incidence of CML per 100 000 inhabitants, year 2002-2010.
Höglund M et al. Blood 2013;122: ©2013 by American Society of Hematology

3 Time trends in percentage of patients treated with TKI by age (A) and by residence (university hospital catchment area vs other area) and sex (B). Time trends in percentage of patients treated with TKI by age (A) and by residence (university hospital catchment area vs other area) and sex (B). Höglund M et al. Blood 2013;122: ©2013 by American Society of Hematology

4 Relative survival by disease phase at diagnosis (A), sex (CP) (B), and age group (CP) (C).
Relative survival by disease phase at diagnosis (A), sex (CP) (B), and age group (CP) (C). Relative survival was calculated as the ratio of the observed survival in the study population to the expected survival of the general population. Höglund M et al. Blood 2013;122: ©2013 by American Society of Hematology

5 Overall (A,C,E) and relative (B,D,F) survival for patients in CP at diagnosis, per Sokal (A-B), Hasford (C-D), and EUTOS (E-F) score. Overall (A,C,E) and relative (B,D,F) survival for patients in CP at diagnosis, per Sokal (A-B), Hasford (C-D), and EUTOS (E-F) score. Differences in survival tested by log-rank test (OS) and Poisson regression model (RS). Höglund M et al. Blood 2013;122: ©2013 by American Society of Hematology

6 RS for patients in CP at diagnosis, by whether or not the patient resided in the catchment area of any of the Swedish university hospitals. RS for patients in CP at diagnosis, by whether or not the patient resided in the catchment area of any of the Swedish university hospitals. Höglund M et al. Blood 2013;122: ©2013 by American Society of Hematology